Key result
Higher vitamin D levels linked to ~10% lower likelihood of peripheral arterial stiffness in CKD.
Why the study?
Vitamin D deficiency and high baPWV independently predict CV events and mortality, but their relationship in non-dialysis stage 3-5 CKD required evaluation.
Is serum 25-hydroxyvitamin D level associated with peripheral arterial stiffness in non-dialysis patients with stage 3-5 CKD?
Cross-Sectional (n=180)
No
Is serum 25-hydroxyvitamin D level associated with peripheral arterial stiffness in non-dialysis patients with stage 3-5 CKD?
Answers are grounded in this paper and cite their sources.
Lower serum 25-hydroxyvitamin D levels and older age are independently associated with increased peripheral arterial stiffness in patients with stage 3-5 CKD.
Vitamin D deficiency and high brachial-ankle pulse wave velocity (baPWV) are each independently associated with higher incidence of mortality and cardiovascular (CV) disease or CV events, respectively. This study aimed to evaluate the relationship between serum 25-hydroxyvitamin D levels and baPWV in non-dialysis patients with stage 3−5 chronic kidney disease (CKD). We enrolled 180 CKD patients. A commercial enzyme-linked immunosorbent assay was used to measure 25-hydroxyvitamin D levels. BaPWV values were measured using an automatic pulse wave analyzer. Either left or right baPWV > 18.0 m/s was considered indicative of peripheral arterial stiffness (PAS). In this study, 73 (40.6%) patients were found to have PAS. Compared to those without PAS (control group), patients with PAS were older and had higher incidence of diabetes mellitus, higher systolic and diastolic blood pressure, higher levels of intact parathyroid hormone, and C-reactive protein, and lower levels of 25-hydroxyvitamin D. Multivariate logistic regression analysis found 25-hydroxyvitamin D levels (odds ratio [OR]: 0.895, 95% confidence interval [CI] 0.828−0.968, p = 0.005) and old age (OR: 1.140, 95% CI 1.088−1.194, p < 0.001) to be independently associated with PAS in patients with stage 3−5 CKD. Lower serum 25-hydroxyvitamin D levels and older age were associated with PAS in these patients.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2022) conducted a cross-sectional in Stage 3-5 Chronic Kidney Disease (CKD) (n=180). Serum 25-hydroxyvitamin D levels vs. Higher serum 25-hydroxyvitamin D levels was evaluated on Peripheral arterial stiffness (PAS), defined as left or right brachial-ankle pulse wave velocity (baPWV) > 18.0 m/s (OR 0.895, 95% CI 0.828-0.968, p=0.005). Higher serum 25-hydroxyvitamin D levels were independently associated with a reduced likelihood of peripheral arterial stiffness in non-dialysis patients with stage 3-5 chronic kidney disease (OR 0.895).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: